GSK (GSK) shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced around claims that its discontinued heartburn medicine Zantac causes cancer.

The London-listed firm said it ꧙had struck agreements to resolve 93%, or about 80,000, of the pending Zantac lawsuits in the U.S. and will make a total payment of up to $2.2 billion to settle those cases. 

GSK Says Plaintiffs ಌUnanimously Recommending Clients Accept Deal

"The participating plaintiff firms are unanimously recommending to their clients that they accept the terms of the State Courts Settlement, which is expected to be fully implemented by the end of H1 2025," GSK said. 

GSK also said it had reached a deal to pay $70 million to settle a Zantac complaint filed by laboratory Valisure, with the agreement subject to final approval from the U.S. Department of Justice (DOJ).

GSK reiterated its previous comments that there 澳洲幸运5开奖号码历史查询:isn't evidence that Zantac "increases the risk of any can༒cer," and said it has not admitted any liability in the settlements. It said the costs of the settlements will be funded "through existing resources" and that there are no changes to its "growth agenda or investment plans."

GSK's 澳洲幸运5开奖号码历史查询:American depositary receipts (ADRs) were little changed in premarꦫket trading but are up around 9% this year.